IVT Launching Cutting Balloon For Highly Resistant Coronary Artery Lesions
This article was originally published in The Gray Sheet
InterVentional Technologies' Cutting Balloon microsurgical dilatation catheter system will be promoted to interventional cardiologists as either a primary, secondary or tertiary treatment for highly resistant coronary arterial lesions, the firm says.
You may also be interested in...
IVT CUTTING BALLOON IS NOT APPROVABLE BASED ON ANGIOPLASTY EQUIVALENCE DATA, FDA PANEL CONCLUDES; FIRM WILL CONTINUE RESTENOSIS REDUCTION STUDY
InterVentional Technologies plans to refocus on demonstrating the potential benefits of the Barath surgical dilatation balloon in reducing coronary artery restenosis as it continues clinical studies of the product. On March 4, FDA's Circulatory System Devices Panel unanimously (8-0) recommended against approval of the device, which is also known as the Cutting Balloon, based on data that attempted to show equivalence to standard balloon angioplasty for coronary artery dilatation.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.